Listar por autor "Giannakoulas, N."
Mostrando ítems 1-11 de 11
-
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients
Katodritou, E.; Terpos, E.; Symeonidis, A. S.; Pouli, A.; Kelaidi, C.; Kyrtsonis, M. C.; Kotsopoulou, M.; Delimpasi, S.; Christoforidou, A.; Giannakoulas, N.; Viniou, N. A.; Stefanoudaki, E.; Hadjiaggelidou, C.; Christoulas, D.; Verrou, E.; Gastari, V.; Papadaki, S.; Polychronidou, G.; Papadopoulou, A.; Giannopoulou, E.; Kastritis, E.; Kouraklis, A.; Konstantinidou, P.; Anagnostopoulos, A.; Zervas, K.; Dimopoulos, M. A. (2014)Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extramedullary plasma cell tumors. The treatment of choice is local radiotherapy (R/T) +/- surgical excision. The role of ... -
FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia
Loules, G.; Kalala, F.; Giannakoulas, N.; Papadakis, E.; Matsouka, P.; Speletas, M. (2009)Background: Primary eosinophlia associated with the FIP1L1-PDGFRA rearrangement represents a subset of chronic eosinophilic leukaemia (CEL) and affected patients are very sensitive to imatinib treatment. This study was ... -
Immunoglobulin D myeloma: Clinical features and outcome in the era of novel agents
Zagouri, F.; Kastritis, E.; Symeonidis, A. S.; Giannakoulas, N.; Katodritou, E.; Delimpasi, S.; Repousis, P.; Terpos, E.; Dimopoulos, M. A. (2014)Objectives: Immunoglobulin D (IgD) multiple myeloma is an uncommon variant of the disease probably associated with poorer prognosis. However, data on IgD myeloma patients treated in the novel agent era are lacking. Methods: ... -
Overexpression of phosphorylated p27(Kip1) at threonine 187 may predict outcome in aggressive B-cell lymphomas
Sirinian, C.; Symeonidis, A.; Giannakoulas, N.; Zolota, V.; Melachrinou, M. (2011)Phosphorylation of p27<SUKip1</SU at threonine 187 (pThr187-p27<SUKip1</SU) occurs frequently in the development of human tumors, directing protein polyubiquitination and subsequent proteasomal degradation. We investigated ... -
Profile of metabolism-related cytokines in myelodysplastic syndromes
Matsouka, P.; Bouronikou, H.; Georgoulias, P.; Palassopoulou, M.; Valotassiou, V.; Vassilopoulos, G.; Giannakoulas, N.; Papadoulis, N. (2009) -
Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab
Arampatzis, S.; Giannakoulas, N.; Liakopoulos, V.; Eleftheriadis, T.; Kourti, P.; Karasavvidou, F.; Matsouka, P.; Stefanidis, I. (2011)Background: Although renal involvement in advanced haematological malignancies is common, glomerulonephritis associated with lymphoproliferative disorders is rare, and the related pathogenetic mechanisms are still poorly ... -
TACI Expression and Signaling in Chronic Lymphocytic Leukemia
Mamara, A.; Germenis, A. E.; Kompoti, M.; Palassopoulou, M.; Mandala, E.; Banti, A.; Giannakoulas, N.; Speletas, M. (2015)TACI is a membrane receptor of BAFF and APRIL, contributing to the differentiation and survival of normal B cells. Although malignant B cells are also subjected on TACI signaling, there is a remarkable intradisease and ... -
TNFRSF13B GENE EXPRESSION AND MOLECULAR ANALYSIS IN B-CELL CHRONIC LYMPHOPROLIFERATIVE DISORDERS
Speletas, M.; Mamara, A.; Kalala, F.; Liadaki, K.; Papadoulis, N.; Kioumi, A.; Giannakoulas, N.; Lafioniatis, S.; Loukidis, K.; Matsouka, P.; Kartasis, Z.; Germenis, A. (2009) -
TNFRSF13B/TACI and TNFRSF13C/BAFFR in B cell chronic lymphocytic leukemia (B-CLL)
Mamara, A.; Kalala, F.; Florou, Z.; Mandala, E.; Palasopoulou, M.; Mpardaka, F.; Giannakoulas, N.; Mpanti, A.; Germenis, A. E.; Speletas, M. (2012) -
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
Katodritou, E.; Terpos, E.; Kelaidi, C.; Kotsopoulou, M.; Delimpasi, S.; Kyrtsonis, M. C.; Symeonidis, A.; Giannakoulas, N.; Stefanoudaki, A.; Christoulas, D.; Chatziaggelidou, C.; Gastari, V.; Spyridis, N.; Verrou, E.; Konstantinidou, P.; Zervas, K.; Dimopoulos, M. A. (2014)Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib-based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety ... -
Treatment with lenalidomide for patients with myelodysplastic syndromes (MDS): report of the Hellenic experience on 73 patients. A retrospective analysis of the Hellenic MDS Study Group
Symeonidis, A.; Galanopoulos, A.; Hatzimichael, E.; Kouraklis, A.; Korantzis, I.; Kartasis, Z.; Giannakoulas, N.; Michali, E.; Kokkini, G.; Vagia, M.; Kotsopoulou, M.; Pappa, V.; Papadaki, E.; Bourantas, K.; Matsouka, P.; Anagnostopoulos, N.; Zoumbos, N.; Hellenic, M. D. S. Study Grp (2009)